NCT02784171 2024-12-10
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Canadian Cancer Trials Group
Phase 2/3 Completed
Canadian Cancer Trials Group
Amphera BV
Polaris Group
Intergroupe Francophone de Cancerologie Thoracique
Boehringer Ingelheim